Results Healthcare has advised Recipharm on the divestment of their API site in Cramlington, UK, to Pharmaron

  • Service: M&A
  • Sector: Healthcare
  • Sub Sector: CROs & CMOs, Pharma & Biotech
  • Engagement Type: Sell Side
Jan 2022
has divested its API manufacturing site in Cramlington, UK, to

Results Healthcare is delighted to announce that it has advised Recipharm, a top five global pharmaceutical CDMO, on the divestment of the Aesica Pharmaceuticals API manufacturing site located in Cramlington, UK, to Pharmaron.

This transaction highlights Results Healthcare’s excellent reputation in the healthcare and life sciences sector and is a testament to our international network. It highlights our deep sector expertise, strong buyer relationships, and outstanding track record of achieving high-value outcomes for our clients.

Recipharm is a world leading CDMO in the pharmaceutical industry, employing almost 9,000 employees across 30+ facilities in 10 countries. It offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and Active Pharmaceutical Ingredients (APIs), pharmaceutical product development as well as development and manufacturing of medical devices. The Aesica Pharmaceuticals Cramlington site near Newcastle, UK, has an established history of cGMP manufacturing services for an array of APIs. The divestment helps Recipharm streamline their operations in line with its ongoing strategy.

Pharmaron has acquired the Cramlington site to further expand its chemistry and manufacturing services and strengthen its global service network. The synergistic integration of the Cramlington site with Pharmaron’s existing service capabilities of discovery, process development and early-stage cGMP API manufacturing at Hoddesdon, will enable a complete end-to-end chemistry and manufacturing service offering in the United Kingdom.

>>>>> Read the press release here

It was a great pleasure working with the Results Healthcare team on this transaction. Their experience, insights and network in the pharmaceutical manufacturing sector was both valuable and key to the successful divestment of Recipharm’s API facility in Cramlington to Pharmaron.

Mark Quick

Head of M&A, Recipharm

Sector Related Deals

Jul 2022
has divested its API site in Rhode Island, USA, to
Jun 2022
A Kester Capital-backed company
has received investment from
Jun 2022
has been acquired by
A company backed by GTCR and The Carlyle Group
May 2022
A subsidiary of Servier
has divested its anti-LAG-3 monoclonal antibody to
A subsidiary of Sino Biopharmaceutical Limited
Mar 2022
has divested its Ringaskiddy, Ireland, manufacturing facility
Mar 2022
has divested its Boucherville, Canada manufacturing facility
Nov 2021
has invested in
company name confidential
Aug 2021
has been acquired by
an Odyssey Investment Partners-backed company
Jun 2021
has acquired a drug product manufacturing facility from